FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC
Pharmaceutical Technology
NOVEMBER 9, 2022
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Patients may receive this therapy regardless of PD-L1 expression or tumour histology.
Let's personalize your content